- Inhibitory Selectivity
|Catalog No.||Product Name||Solubility(25°C)|
|S7111||NLG919||<1 mg/mL||15 mg/mL||30 mg/mL|
|S7756||Indoximod (NLG-8189）||<1 mg/mL||1 mg/mL||<1 mg/mL|
|S7910||Epacadostat (INCB024360)||<1 mg/mL||87 mg/mL||53 mg/mL|
|S7587||INCB024360 analogue||<1 mg/mL||54 mg/mL||54 mg/mL|
|S8657||PF-06840003||<1 mg/mL||46 mg/mL||6 mg/mL|
- IDO Inhibitors (5)
- New IDO Products
|Catalog No.||Information||Product Use Citations||Product Validations|
NLG919 is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM in cell-free assays. Phase 1.
Inhibitor sensitivity of tryptophan 2,3-dioxygenase (TDO) in N-formylkynurenine (NFK) Green assay. Dose-response curves of INCB024360, S7111, and NTRC 0820-0 with IC50 values 67 nM and 75 nM, respectively.
Indoximod (NLG-8189), a methylated tryptophan, acts as an IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, and reverses IDO-mediated immune suppression. Phase 2.
Epacadostat (INCB024360) is a potent and selective indoleamine 2,3-dioxygenase (IDO1) inhibitor with IC50 of 10 nM and displays high selectivity over other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO).
Macrophages were treated with 2 μM obatoclax, 0.1 μM SNS-032, 3 μM SaliPhe, 0.1 μM JNJ872, 1 μM gemcitabine, 1 μM epacadostat or 1 μM NLG919 or remained non-treated and infected with mock or IAV (moi 3). After 24 h cell viability was measured by CTG and results were plotted. Mean ± SD, n=3.
INCB024360 analogue is a potent, competitive IDO1 (indoleamine-(2,3)-dioxygenase) inhibitor with IC50 of 67 nM. Phase 2.
PF-06840003 is a highly selective orally bioavailable IDO-1 inhibitor. Although it has moderate hIDO1 enzyme inhibition (IC50 0.41 μM), it is a highly efficient compound (LE 0.53, LipE 5.1), driven by its tight packing within the enzyme, as well as the high density of hydrogen bonds it forms with hIDO-1 despite its small size.